Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unnecessary Use of Corticosteroids for managing early mild symptoms of COVID-19 may lead to Rhino-ortibal-cerebral mucormycosis in Patients with Diabetes - a case series from Lahore, Pakistan.
Iqtadar S, Hashmat M, Chaudhry MNA, Mumtaz SU, Abaidullah S, Pascual-Figal DA, Khan A. Iqtadar S, et al. Ther Adv Infect Dis. 2022 May 6;9:20499361221097417. doi: 10.1177/20499361221097417. eCollection 2022 Jan-Dec. Ther Adv Infect Dis. 2022. PMID: 35547833 Free PMC article.
Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial.
Di Pierro F, Iqtadar S, Khan A, Ullah Mumtaz S, Masud Chaudhry M, Bertuccioli A, Derosa G, Maffioli P, Togni S, Riva A, Allegrini P, Khan S. Di Pierro F, et al. Among authors: iqtadar s. Int J Gen Med. 2021 Jun 24;14:2807-2816. doi: 10.2147/IJGM.S318949. eCollection 2021. Int J Gen Med. 2021. PMID: 34194240 Free PMC article. Clinical Trial.
Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19-Results From a Pilot Open-Label, Randomized Controlled Trial.
Khan A, Iqtadar S, Mumtaz SU, Heinrich M, Pascual-Figal DA, Livingstone S, Abaidullah S. Khan A, et al. Among authors: iqtadar s. Front Pharmacol. 2022 Jun 7;13:898062. doi: 10.3389/fphar.2022.898062. eCollection 2022. Front Pharmacol. 2022. PMID: 35747751 Free PMC article.
Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial.
Di Pierro F, Khan A, Iqtadar S, Mumtaz SU, Chaudhry MNA, Bertuccioli A, Derosa G, Maffioli P, Togni S, Riva A, Allegrini P, Recchia M, Zerbinati N. Di Pierro F, et al. Among authors: iqtadar s. Front Pharmacol. 2023 Jan 13;13:1096853. doi: 10.3389/fphar.2022.1096853. eCollection 2022. Front Pharmacol. 2023. PMID: 36712674 Free PMC article.
28 results